secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0000012208-22-000040
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q2 revenue $691M down 3.5% YoY; non-GAAP EPS $3.38; raises FY22 revenue outlook; adds $200M buyback
--------------------------------------------------------------------------------

- Q2 GAAP net loss $927M ($31.12/diluted) vs income $914M ($30.32) last year; non-GAAP net income $101M ($3.38) vs $107M ($3.54).
- Reported sales $691.1M down 3.5% YoY; currency-neutral core sales (ex-COVID) up 5.7%.
- Life Science $322M (-3.5% reported, +0.5% constant); Clinical Diag $368M (-3.3%, +0.7% constant).
- FY22 guidance: non-GAAP currency-neutral revenue growth at high end of 1-2%; COVID rev ~$93M (up); op margin ~19% reaffirmed.
- Board authorized additional $200M share repurchase; total available $298.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220822000040/0000012208-22-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220822000040/bio-20220728.htm
  HTML page:      https://secwatch.observer/filing/0000012208-22-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer